Eli Lilly Faces Market Pressure Following Weight-Loss Drug Approval

Eli Lilly's fast FDA approval for weight-loss drug Foundayo faces immediate data attack from Novo Nordisk's Wegovy and analyst sales forecast cuts, as commercial launch begins.

Eli Lilly has achieved a significant regulatory milestone with the expedited FDA approval of its new weight-loss medication, Foundayo. However, the celebration surrounding this record-speed authorization has been swiftly overshadowed. The pharmaceutical giant now contends with a targeted data campaign from rival Novo Nordisk and a wave of downward revisions to the drug's sales forecasts from financial analysts.

Competitive Tensions Escalate

The U.S. Food and Drug Administration greenlit Foundayo through a new priority program in just one to two months, marking the fastest approval of its kind since 2002. Novo Nordisk responded immediately to this competitive advance. The Danish company released a cross-study analysis claiming its own Wegovy pill delivers a 3.2 percentage point greater reduction in body weight. Furthermore, the presented data indicated a 14-fold higher risk of patients discontinuing Foundayo treatment due to adverse side effects.

In defense, Eli Lilly emphasizes the convenience of its therapy. Patients taking Wegovy must administer the injection on an empty stomach in the morning, whereas Foundayo imposes no restrictions related to food intake or timing of the dose. Company leadership positions this flexibility as a critical advantage for patient adherence and daily routine integration.

Financial Forecasts Adjusted

The intensifying rivalry is already influencing projections on Wall Street. Analysts at RBC Capital Markets have substantially lowered their 2026 revenue estimate for Foundayo, cutting it from $4 billion to $1.6 billion. Meanwhile, BMO Capital Markets characterized the approval as a crucial step for Eli Lilly's metabolic portfolio, enabling direct competition with Wegovy. BMO reaffirmed its $1,300 price target for the company's shares. The current market uncertainty is reflected in the stock's performance. Having declined over twelve percent since the start of the year, the equity now trades approximately 15 percent below its 52-week high.

Pricing Debate and Commercial Launch

Beyond the commercial battle, CEO Dave Ricks is engaging on a separate front. He has publicly opposed White House proposals to legislatively enact a "most favored nation" clause for drug pricing. Ricks cautioned that such policies could inflict long-term damage on U.S.-based research and development, pledging to use all available means to challenge the initiative.

Despite this political controversy, the drug's commercial rollout is proceeding as scheduled. Shipments of Foundayo will commence this coming Monday, April 6, via the company's direct-to-consumer platform, LillyDirect. Priced at $25 for commercially insured patients, Eli Lilly's oral therapy now directly challenges the injectable Wegovy, which has already been prescribed to over 600,000 patients in the United States since January.